It’s not uncommon for liver cancer to come back even after treatment for hepatitis C with direct-acting antivirals was successful.
High rates of cancer recurrence are common in patients with hepatitis C and prior hepatocellular carcinoma who underwent treatment with direct-acting antivirals (DAA), according to research published in the Journal of Hepatology.
María Reig, MD, of the Barcelona Clinic Liver Cancer Group, and colleagues conducted a study of 103 patients with hepatitis C and a prior history of treated hepatocellular carcinoma; the patients had previously achieved complete response and lacked non-characterized nodules at the time of treatment with all-oral DAAs.
Fifty-eight patients met the study’s inclusion criteria. The researchers conducted a median follow-up of 5.7 months, in which 3 patients died and 16 patients (27.6%) developed a radiologic tumor recurrence. Of those 16 patients, 3 developed an intrahepatic growth. New intrahepatic lesions were found in 5 patients (1 nodule), 4 of whom developed up to 3 nodules less than or equal to 3 cm and one of whom developed a multifocal nodule. Three patients developed an infiltrative ill-defined hepatocellular carcinoma.
|Read Full Article: Tumor recurrence is common in patients with hepatitis C, hepatocellular carcinoma – The Clinical Advisor|